Although a large number of studies on the TMPRSS2, ERG fusion gene are considered to be new biomarkers, therapeutic targets, diagnostic and prognostic indicators for prostate cancer, and two recent studies have used public databases to explore the expression pattern, prognostic value and immune infiltration of TMPRSS2 in prostate cancer, but these studies are limited to prostate cancer and cannot fully reflect all tumours.42, 43. This evidence concerns the gene TMPRSS2 and Familial prostate cancer.